期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 60, 期 17, 页码 1623-1630出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.07.021
关键词
bypass; clopidogrel; myocardial infarction; surgery; ticagrelor
资金
- AstraZeneca
- Merck
- Johnson Johnson
- Bayer
- Daiichi Sankyo
- Bristol-Myers Squibb
- Gilead Sciences
- Novartis
- Covidien
- Boehringer-Ingelheim
- Eli Lilly Company
- GlaxoSmithKline
- Pozen
- Regado Biotechnologies
- Sanofi Aventis
- Schering Plough
- Medicines Company
- Regado
- MSD
- Accumetrics
- Essentialis
- Regeneron
- Takeda
- Merck/Schering-Plough
- Bristol-Myers Squibb/Pfizer
- Schering-Plough/Merck
- Roche
Objectives This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Background In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had significantly lower total and cardiovascular mortality. Methods In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically identified bleeding or infection events that either caused or subsequently contributed to death. Results Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infection (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more common in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p < 0.05, and bleeding: 27 vs. 9, p < 0.01, for clopidogrel and ticagrelor, respectively). Conclusions The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872) (J Am Coll Cardiol 2012;60:1623-30) (c) 2012 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据